



## ARDEX EG800F Part A

### ARDEX (Ardex Australia)

Chemwatch Hazard Alert Code: 2

Chemwatch: 7928-43

Version No: 2.1

Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

Issue Date: 24/10/2024

Print Date: 24/10/2024

L.GHS.AUS.EN.E

#### SECTION 1 Identification of the substance / mixture and of the company / undertaking

##### Product Identifier

Product name	ARDEX EG800F Part A
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains bisphenol A diglycidyl ether and bisphenol A diglycidyl ether resin, liquid)
Chemical formula	Not Applicable
Other means of identification	Not Available

##### Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	The epoxy resin of the 3-part Commercial Epoxy Grout. Use according to manufacturer's directions.
--------------------------	--

##### Details of the manufacturer or supplier of the safety data sheet

Registered company name	ARDEX (Ardex Australia)
Address	2 Buda Way Kemp Creek NSW 2147 Australia
Telephone	1300 788 780
Fax	1300 780 102
Website	<a href="http://www.ardexaustralia.com">www.ardexaustralia.com</a>
Email	<a href="mailto:technical.services@ardexaustralia.com">technical.services@ardexaustralia.com</a>

##### Emergency telephone number

Association / Organisation	ARDEX (ARDEX Australia)
Emergency telephone number(s)	1800 224 070 (Mon-Fri, 9am-5pm)
Other emergency telephone number(s)	Not Available

#### SECTION 2 Hazards identification

##### Classification of the substance or mixture

**HAZARDOUS CHEMICAL. DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.**

Poisons Schedule	S5
Classification <sup>[1]</sup>	Skin Corrosion/Irritation Category 2, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2A, Germ Cell Mutagenicity Category 2, Carcinogenicity Category 2, Specific Target Organ Toxicity - Repeated Exposure Category 1, Hazardous to the Aquatic Environment Long-Term Hazard Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

##### Label elements

Hazard pictogram(s)	
Signal word	Danger

##### Hazard statement(s)

H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H341	Suspected of causing genetic defects.
H351	Suspected of causing cancer.
H372	Causes damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.
AUH019	May form explosive peroxides.

**Precautionary statement(s) Prevention**

P201	Obtain special instructions before use.
P260	Do not breathe mist/vapours/spray.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.
P264	Wash all exposed external body areas thoroughly after handling.
P272	Contaminated work clothing should not be allowed out of the workplace.

**Precautionary statement(s) Response**

P308+P313	IF exposed or concerned: Get medical advice/ attention.
P302+P352	IF ON SKIN: Wash with plenty of water.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P314	Get medical advice/attention if you feel unwell.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P391	Collect spillage.

**Precautionary statement(s) Storage**

P405	Store locked up.
------	------------------

**Precautionary statement(s) Disposal**

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

**SECTION 3 Composition / information on ingredients****Substances**

See section below for composition of Mixtures

**Mixtures**

CAS No	%[weight]	Name
25068-38-6	>60	<u>bisphenol A diglycidyl ether resin, liquid</u>
1675-54-3	10-30	<u>bisphenol A diglycidyl ether</u>
26761-45-5	1-10	<u>glycidyl neodecanoate</u>
39817-09-9	1-10	<u>bisphenol F diglycidyl ether (isomers)</u>
68609-97-2	1-10	<u>(C12-14)alkylglycidyl ether</u>
2210-79-9	1-10	<u>cresyl glycidyl ether</u>
<b>Legend:</b>	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available	

**SECTION 4 First aid measures****Description of first aid measures**

<b>Eye Contact</b>	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> <li>▶ Wash out immediately with fresh running water.</li> <li>▶ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>▶ Seek medical attention without delay; if pain persists or recurs seek medical attention.</li> <li>▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
<b>Skin Contact</b>	<p>If skin contact occurs:</p> <ul style="list-style-type: none"> <li>▶ Immediately remove all contaminated clothing, including footwear.</li> <li>▶ Flush skin and hair with running water (and soap if available).</li> <li>▶ Seek medical attention in event of irritation.</li> </ul>
<b>Inhalation</b>	<ul style="list-style-type: none"> <li>▶ If fumes, aerosols or combustion products are inhaled remove from contaminated area.</li> <li>▶ Other measures are usually unnecessary.</li> </ul>
<b>Ingestion</b>	<ul style="list-style-type: none"> <li>▶ For advice, contact a Poisons Information Centre or a doctor at once.</li> <li>▶ Urgent hospital treatment is likely to be needed.</li> <li>▶ <b>If swallowed do NOT induce vomiting.</b></li> </ul>

- ▶ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.
- ▶ Observe the patient carefully.
- ▶ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.
- ▶ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.
- ▶ Transport to hospital or doctor without delay.

#### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

### SECTION 5 Firefighting measures

#### Extinguishing media

- ▶ Foam.
- ▶ Dry chemical powder.
- ▶ BCF (where regulations permit).
- ▶ Carbon dioxide.
- ▶ Water spray or fog - Large fires only.

#### Special hazards arising from the substrate or mixture

- |                             |  |
|-----------------------------|--|
| <b>Fire Incompatibility</b> | ▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result |
|-----------------------------|--|

#### Advice for firefighters

<b>Fire Fighting</b>	<ul style="list-style-type: none"> <li>▶ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▶ Wear full body protective clothing with breathing apparatus.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water course.</li> <li>▶ Use water delivered as a fine spray to control fire and cool adjacent area.</li> <li>▶ Avoid spraying water onto liquid pools.</li> <li>▶ <b>DO NOT</b> approach containers suspected to be hot.</li> <li>▶ Cool fire exposed containers with water spray from a protected location.</li> <li>▶ If safe to do so, remove containers from path of fire.</li> </ul>
<b>Fire/Explosion Hazard</b>	<ul style="list-style-type: none"> <li>▶ Combustible.</li> <li>▶ Slight fire hazard when exposed to heat or flame.</li> <li>▶ Heating may cause expansion or decomposition leading to violent rupture of containers.</li> <li>▶ On combustion, may emit toxic fumes of carbon monoxide (CO).</li> <li>▶ May emit acrid smoke.</li> <li>▶ Mists containing combustible materials may be explosive.</li> </ul> <p>Combustion products include: carbon dioxide (CO<sub>2</sub>) aldehydes other pyrolysis products typical of burning organic material.</p>
<b>HAZCHEM</b>	•3Z

### SECTION 6 Accidental release measures

#### Personal precautions, protective equipment and emergency procedures

See section 8

#### Environmental precautions

See section 12

#### Methods and material for containment and cleaning up

<b>Minor Spills</b>	<p>Environmental hazard - contain spillage.</p> <ul style="list-style-type: none"> <li>▶ Clean up all spills immediately.</li> <li>▶ Avoid breathing vapours and contact with skin and eyes.</li> <li>▶ Control personal contact with the substance, by using protective equipment.</li> <li>▶ Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>▶ Wipe up.</li> <li>▶ Place in a suitable, labelled container for waste disposal.</li> </ul>
<b>Major Spills</b>	<p>Environmental hazard - contain spillage. Moderate hazard.</p> <ul style="list-style-type: none"> <li>▶ Clear area of personnel and move upwind.</li> <li>▶ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▶ Wear breathing apparatus plus protective gloves.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water course.</li> <li>▶ No smoking, naked lights or ignition sources.</li> <li>▶ Increase ventilation.</li> <li>▶ Stop leak if safe to do so.</li> <li>▶ Contain spill with sand, earth or vermiculite.</li> <li>▶ Collect recoverable product into labelled containers for recycling.</li> <li>▶ Absorb remaining product with sand, earth or vermiculite.</li> <li>▶ Collect solid residues and seal in labelled drums for disposal.</li> <li>▶ Wash area and prevent runoff into drains.</li> <li>▶ If contamination of drains or waterways occurs, advise emergency services.</li> </ul>

Personal Protective Equipment advice is contained in Section 8 of the SDS.

### SECTION 7 Handling and storage

#### Precautions for safe handling

- |                      |  |
|----------------------|--|
| <b>Safe handling</b> | <ul style="list-style-type: none"> <li>▶ <b>DO NOT</b> allow clothing wet with material to stay in contact with skin</li> <li>▶ Avoid all personal contact, including inhalation.</li> </ul> |
|----------------------|--|

Continued...

	<ul style="list-style-type: none"> <li>▶ Wear protective clothing when risk of exposure occurs.</li> <li>▶ Use in a well-ventilated area.</li> <li>▶ Prevent concentration in hollows and sumps.</li> <li>▶ <b>DO NOT enter confined spaces until atmosphere has been checked.</b></li> <li>▶ Avoid smoking, naked lights or ignition sources.</li> <li>▶ Avoid contact with incompatible materials.</li> <li>▶ When handling, <b>DO NOT eat, drink or smoke.</b></li> <li>▶ Keep containers securely sealed when not in use.</li> <li>▶ Avoid physical damage to containers.</li> <li>▶ Always wash hands with soap and water after handling.</li> <li>▶ Work clothes should be laundered separately.</li> <li>▶ Use good occupational work practice.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.</li> </ul>
<b>Other information</b>	<ul style="list-style-type: none"> <li>▶ Store in original containers.</li> <li>▶ Keep containers securely sealed.</li> <li>▶ No smoking, naked lights or ignition sources.</li> <li>▶ Store in a cool, dry, well-ventilated area.</li> <li>▶ Store away from incompatible materials and foodstuff containers.</li> <li>▶ Protect containers against physical damage and check regularly for leaks.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

**Conditions for safe storage, including any incompatibilities**

<b>Suitable container</b>	<ul style="list-style-type: none"> <li>▶ Metal can or drum</li> <li>▶ Packaging as recommended by manufacturer.</li> <li>▶ Check all containers are clearly labelled and free from leaks.</li> </ul>
<b>Storage incompatibility</b>	<ul style="list-style-type: none"> <li>▶ Avoid cross contamination between the two liquid parts of product (kit).</li> <li>▶ If two part products are mixed or allowed to mix in proportions other than manufacturer's recommendation, polymerisation with gelation and evolution of heat (exotherm) may occur.</li> <li>▶ This excess heat may generate toxic vapour</li> <li>▶ Avoid reaction with amines, mercaptans, strong acids and oxidising agents</li> </ul>

**SECTION 8 Exposure controls / personal protection****Control parameters****Occupational Exposure Limits (OEL)****INGREDIENT DATA**

Not Available

Ingredient	Original IDLH	Revised IDLH
bisphenol A/ diglycidyl ether resin, liquid	Not Available	Not Available
bisphenol A diglycidyl ether	Not Available	Not Available
glycidyl neodecanoate	Not Available	Not Available
bisphenol F diglycidyl ether (isomers)	Not Available	Not Available
(C12-14)alkylglycidyl ether	Not Available	Not Available
cresyl glycidyl ether	Not Available	Not Available

**Occupational Exposure Banding**

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
bisphenol A/ diglycidyl ether resin, liquid	E	≤ 0.1 ppm
bisphenol A diglycidyl ether	E	≤ 0.1 ppm
glycidyl neodecanoate	E	≤ 0.1 ppm
bisphenol F diglycidyl ether (isomers)	E	≤ 0.1 ppm
(C12-14)alkylglycidyl ether	E	≤ 0.1 ppm
cresyl glycidyl ether	E	≤ 0.1 ppm

**Notes:**

Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

**MATERIAL DATA****Exposure controls**

<b>Appropriate engineering controls</b>	<p>Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are:</p> <p>Process controls which involve changing the way a job activity or process is done to reduce the risk.</p> <p>Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.</p> <p>Employers may need to use multiple types of controls to prevent employee overexposure.</p> <p>General exhaust is adequate under normal operating conditions. Local exhaust ventilation may be required in specific circumstances. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.</p> <p>Type of Contaminant: _____</p>	<p>Air Speed: _____</p>
---	--	-------------------------

Continued...

solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

#### Individual protection measures, such as personal protective equipment



#### Eye and face protection

- ▶ Safety glasses with side shields.
- ▶ Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

#### Skin protection

See Hand protection below

#### Hands/feet protection

##### NOTE:

- ▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- ▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

· When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

· When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

· Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.

· Contaminated gloves should be replaced.

As defined in ASTM F-739-96 in any application, gloves are rated as:

- Excellent when breakthrough time > 480 min
- Good when breakthrough time > 20 min
- Fair when breakthrough time < 20 min
- Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task.

Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

· Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.

· Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

When handling liquid-grade epoxy resins wear chemically protective gloves, boots and aprons.

The performance, based on breakthrough times, of:

- Ethyl Vinyl Alcohol (EVAL laminate) is generally excellent
- Butyl Rubber ranges from excellent to good
- Nitrile Butyl Rubber (NBR) from excellent to fair.
- Neoprene from excellent to fair
- Polyvinyl (PVC) from excellent to poor

As defined in ASTM F-739-96

	<ul style="list-style-type: none"> <li>· Excellent breakthrough time &gt; 480 min</li> <li>· Good breakthrough time &gt; 20 min</li> <li>· Fair breakthrough time &lt; 20 min</li> <li>· Poor glove material degradation</li> </ul> <p>Gloves should be tested against each resin system prior to making a selection of the most suitable type. Systems include both the resin and any hardener, individually and collectively)</p> <ul style="list-style-type: none"> <li>· <b>DO NOT use cotton or leather (which absorb and concentrate the resin), natural rubber (latex), medical or polyethylene gloves (which absorb the resin).</b></li> <li>· <b>DO NOT use barrier creams containing emulsified fats and oils as these may absorb the resin; silicone-based barrier creams should be reviewed prior to use.</b></li> </ul> <p>Replacement time should be considered when selecting the most appropriate glove. It may be more effective to select a glove with lower chemical resistance but which is replaced frequently than to select a more resistant glove which is reused many times</p>
<b>Body protection</b>	See Other protection below
<b>Other protection</b>	<ul style="list-style-type: none"> <li>▶ Overalls.</li> <li>▶ P.V.C apron.</li> <li>▶ Barrier cream.</li> <li>▶ Skin cleansing cream.</li> <li>▶ Eye wash unit.</li> </ul>

### Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1 P2	-
up to 50	1000	-	A-AUS / Class 1 P2
up to 50	5000	Airline *	-
up to 100	5000	-	A-2 P2
up to 100	10000	-	A-3 P2
100+			Airline**

\* - Continuous Flow \*\* - Continuous-flow or positive pressure demand

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO<sub>2</sub>), G = Agricultural chemicals, K = Ammonia(NH<sub>3</sub>), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- ▶ Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- ▶ The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- ▶ Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

## SECTION 9 Physical and chemical properties

### Information on basic physical and chemical properties

Appearance	Liquid.		
Physical state	Liquid	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Applicable	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Not Available	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available
Heat of Combustion (kJ/g)	Not Available	Ignition Distance (cm)	Not Available
Flame Height (cm)	Not Available	Flame Duration (s)	Not Available
Enclosed Space Ignition Time Equivalent (s/m <sup>3</sup> )	Not Available	Enclosed Space Ignition Deflagration Density (g/m <sup>3</sup> )	Not Available

## SECTION 10 Stability and reactivity

Reactivity	See section 7
------------	---------------

<b>Chemical stability</b>	<ul style="list-style-type: none"> <li>▶ Unstable in the presence of incompatible materials.</li> <li>▶ Product is considered stable.</li> <li>▶ Hazardous polymerisation will not occur.</li> </ul>
<b>Possibility of hazardous reactions</b>	See section 7
<b>Conditions to avoid</b>	See section 7
<b>Incompatible materials</b>	See section 7
<b>Hazardous decomposition products</b>	See section 5

## SECTION 11 Toxicological information

### Information on toxicological effects

<b>Inhaled</b>	<p>The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified by EC Directives using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.</p> <p>Inhalation hazard is increased at higher temperatures.</p>
<b>Ingestion</b>	<p>The material has <b>NOT</b> been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.</p>
<b>Skin Contact</b>	<p>The material may accentuate any pre-existing dermatitis condition</p> <p>Repeated exposure may cause skin cracking, flaking or drying following normal handling and use.</p> <p>Open cuts, abraded or irritated skin should not be exposed to this material</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p> <p>The material produces mild skin irritation; evidence exists, or practical experience predicts, that the material either</p> <ul style="list-style-type: none"> <li>▶ produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or</li> <li>▶ produces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period.</li> </ul> <p>Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p>
<b>Eye</b>	<p>Evidence exists, or practical experience predicts, that the material may cause severe eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Eye contact may cause significant inflammation with pain. Corneal injury may occur; permanent impairment of vision may result unless treatment is prompt and adequate. Repeated or prolonged exposure to irritants may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p>
<b>Chronic</b>	<p>On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.</p> <p>Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.</p> <p>Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.</p> <p>Substances that can cause occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers. Wherever it is reasonably practicable, exposure to substances that can cause occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.</p> <p>Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.</p> <p>Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.</p> <p>Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests.</p> <p>Prolonged or repeated skin contact may cause drying with cracking, irritation and possible dermatitis following.</p> <p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p> <p>Exposure to the material may cause concerns for human fertility, on the basis that similar materials provide some evidence of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects, but which are not a secondary non-specific consequence of other toxic effects.</p> <p>The polymer contained in this product has reactive groups (aldehydes and phenolics) generally considered to be of moderate concern (US EPA).</p> <p>In general, aldehydes are reactive. Due to their water solubility and severe irritant properties, the lower aldehydes attack exposed moist tissue, particularly the eyes and mucous membranes of the upper respiratory tract. Aldehydes can also be skin and respiratory sensitisers, e.g. formaldehyde and glutaraldehyde. Lower solubility aldehydes can penetrate further into the lungs. Skin sensitisation reactions have been noted after exposure to urea-formaldehyde resins.</p> <p>Phenolic groups with ortho and para positions free from substitution are reactive; this is because the ortho and para positions on the aromatic ring are highly activated by the phenolic hydroxyl group and are therefore readily substituted.</p> <p>The acute toxicity of polymers of the group with a molecular weight above 1000 is expected to be lower. Whilst it is generally accepted that polymers with a molecular weight exceeding 1000 are unlikely to pass through biological membranes, oligomers with lower molecular weight and specifically, those with a molecular weight below 500, may. Estimations based on a "highly" dispersed polymer population suggest that a polymer of approximate molecular weight 1000 could contain no more than one reactive group of moderate concern for it to be regulated as a polymer of low concern (a so-called PLC) 2500). Polymers with a molecular weight above 10000 are generally considered to be PLCs because these are not expected to be absorbed by biological systems. The choice of 10000 as a cut-off value is thought to provide a safety factor of 100, regarded as reasonable in light of limited data, duration of studies, dose levels at which effects are seen, and extrapolation from animals to humans.</p> <p>All glycidyl ethers show genotoxic potential due their alkylating properties. Those glycidyl ethers that have been investigated in long term studies exhibit more or less marked carcinogenic potential. Alkylating agents may damage the stem cell which acts as the precursor to components of the blood. Loss of the stem cell may result in pancytopenia (a reduction in the number of red and white blood cells and platelets) with a latency period corresponding to the lifetime of the individual blood cells. Granulocytopenia (a reduction in granular</p>

Continued...



leukocytes) develops within days and thrombocytopenia (a disorder involving platelets), within 1-2 weeks, whilst loss of erythrocytes (red blood cells) need months to become clinically manifest. Aplastic anaemia develops due to complete destruction of the stem cells. Reported adverse effects in laboratory animals include sensitization, and skin and eye irritation, as well as mutagenic and tumorigenic activity.

Testicular abnormalities (including testicular atrophy with decreased spermatogenic activity) following exposure to glycidyl ethers have been reported. Haemopoietic abnormalities following exposure to glycidyl ethers, including alteration of the leukocyte count, atrophy of lymphoid tissue, and bone marrow cytotoxicity have also been reported. These abnormalities were usually observed along with pneumonia and/or toxemia, and therefore may be secondary effects. However, especially in light of the generalized reduction in leukocytes and the atrophy of lymphoid tissues, the observed haemopoietic abnormalities may have been predisposing factors to pneumonia. While none of the individual research reports are conclusive with respect to the ability of glycidyl ethers to produce permanent changes to the testes or haemopoietic system in laboratory animals, the pattern of displayed effects is reason for concern

Glycidyl ethers have been shown to cause allergic contact dermatitis in humans. Glycidyl ethers generally cause skin sensitization in experimental animals. Necrosis of the mucous membranes of the nasal cavities was induced in mice exposed to allyl glycidyl ether.

A study of workers with mixed exposures was inconclusive with regard to the effects of specific glycidyl ethers. Phenyl glycidyl ether, but not n-butyl glycidyl ether, induced morphological transformation in mammalian cells in vitro. n-Butyl glycidyl ether induced micronuclei in mice in vivo following intraperitoneal but not oral administration. Phenyl glycidyl ether did not induce micronuclei or chromosomal aberrations in vivo or chromosomal aberrations in animal cells in vitro. Alkyl C12 or C14 glycidyl ether did not induce DNA damage in cultured human cells or mutation in cultured animal cells. Allyl glycidyl ether induced mutation in *Drosophila*. The glycidyl ethers were generally mutagenic to bacteria.

The material contains a substantial proportion of a polymer considered to be of low concern (PLC). The trend towards production of lower molecular weight polymers (thus reducing the required level of solvent use and creating a more "environmentally-friendly" material) has brought with it the need to define PLCs as those

having molecular weights of between 1000 and 10000 and containing less than 10% of the molecules with molecular weight below 500 and less than 25% of the molecules with a molecular weight below 1000. These may contain unlimited low concern functional groups or moderate concern reactive functional groups with a combined functional group equivalent weight (FGEW, a concept developed by the US EPA describing whether the reactive functional group is sufficiently diluted by polymeric material) of a 1000 or more (provided no high concern groups are present) or high concern reactive functional groups with a FGEW of 5000 or more (FGEW includes moderate concern groups if present).

having molecular weights exceeding 10000 (without restriction on reactive groups).

Inhalation of polymers with molecular weights > 70,000 Da has been linked with irreversible lung damage due to lung overloading and impaired clearance of particles from the lung, particularly following repeated exposure. If the polymer is inhaled at low levels and/or infrequently, it is assumed that it will be cleared from the lungs.

Reactive functional groups are in turn classified as being of low, moderate or high concern. Classification of the polymer as a PLC, in accordance with established criteria, does not mean that hazards will not be associated with the polymer (during its import, manufacture, use, storage, handling or disposal). The polymer may, for example, contain a large number of particles in the respirable range, a hazard which may need to be assessed in the health and safety risk assessment. Similarly a polymer with low concern reactive may be released into the environment in large quantities and produce an environmental hazard.

Whilst it is generally accepted that polymers with a molecular weight exceeding 1000 are unlikely to pass through biological membranes, oligomers with lower molecular weight and specifically, those with a molecular weight below 500, may. Estimations based on a "highly" dispersed polymer population (polydispersity = 10) suggests that the molecular weight of the polymer carrying a reactive group of high concern must be 5000 to be considered a PLC; similarly a polymer of approximate molecular weight 1000 could contain no more than one reactive group of moderate concern (for two moderate concern groups, the molecular weight would be about 2500).

Bisphenol A diglycidyl ethers (BADGEs) produce sensitisation dermatitis characterised by a papular, vesicular eczema with considerable itching of the back of the hand, the forearm and face and neck. This lesion may persist for 10-14 days after withdrawal from exposure and recur immediately on re-exposure. This dermatitis may persist for longer periods following each exposure but is unlikely to become more intense. Lesions may develop a brownish colour and scaling occurs frequently. Lower molecular weight species produce sensitisation more readily.

In mice technical grades of bisphenol A diglycidyl ether produced epidermal tumours and a small increase in the incidence kidney tumours in males and of lymphoreticular/ haematopoietic tumours in females. Subcutaneous injection produced a small number of fibrosarcomas in rats.

BADGE is listed as an IARC Group 3 carcinogen, meaning it is "not classifiable as to its carcinogenicity to humans". Concern has been raised over this possible carcinogenicity because BADGE is used in epoxy resins in the lining of some tin cans for foodstuffs, and unreacted BADGE may end up in the contents of those cans.

For some reactive diluents, prolonged or repeated skin contact may result in absorption of potentially harmful amounts or allergic skin reactions

Exposure to some reactive diluents (notably neopentylglycol diglycidyl ether, CAS RN:17557-23-2) has caused cancer in some animal testing.

Bisphenol A exhibits hormone-like properties that raise concern about its suitability in consumer products and food containers. Bisphenol A is thought to be an endocrine disruptor which can mimic oestrogen and may lead to negative health effects. More specifically, bisphenol A closely mimics the structure and function of the hormone oestradiol with the ability to bind to and activate the same oestrogen receptor as the natural hormone. The presence of the p-hydroxy group on the benzene rings is thought to be responsible for the oestradiol mimicry.

Early developmental stages appear to be the period of greatest sensitivity to its effects and some studies have linked prenatal exposure to later physical and neurological difficulties. Regulatory bodies have determined safety levels for humans, but those safety levels are being questioned or are under review.

A 2009 study on Chinese workers in bisphenol A factories found that workers were four times more likely to report erectile dysfunction, reduced sexual desire and overall dissatisfaction with their sex life than workers with no heightened bisphenol A exposure. Bisphenol A workers were also seven times more likely to have ejaculation difficulties. They were also more likely to report reduced sexual function within one year of beginning employment at the factory, and the higher the exposure, the more likely they were to have sexual difficulties.

Bisphenol A in weak concentrations is sufficient to produce a negative reaction on the human testicle. The researchers found that a concentration equal to 2 ug/ litre of bisphenol A in the culture medium, a concentration equal to the average concentration generally found in the blood, urine and amniotic fluid of the population, was sufficient to produce the effects. The researchers believe that exposure of pregnant women to bisphenol A may be one of the causes of congenital masculinisation defects of the hypospadias and cryptorchidism types the frequency of which has doubled overall since the 70's. They also suggested that "it is also possible that bisphenol A contributes to a reduction in the production of sperm and the increase in the incidence of testicular cancer in adults that have been observed in recent decades"

One review has concluded that obesity may be increased as a function of bisphenol A exposure, which "...merits concern among scientists and public health officials"

One study demonstrated that adverse neurological effects occur in non-human primates regularly exposed to bisphenol A at levels equal to the United States Environmental Protection Agency's (EPA) maximum safe dose of 50 ug/kg/day This research found a connection between bisphenol A and interference with brain cell connections vital to memory, learning, and mood.

A further review concluded that bisphenol-A has been shown to bind to thyroid hormone receptor and perhaps have selective effects on its functions. Carcinogenicity studies have shown increases in leukaemia and testicular interstitial cell tumours in male rats. However, "these studies have not been considered as convincing evidence of a potential cancer risk because of the doubtful statistical significance of the small differences in incidences from controls". Another in vitro study has concluded that bisphenol A is able to induce neoplastic transformation in human breast epithelial cells. [whilst a further study concluded that maternal oral exposure to low concentrations of bisphenol A, during lactation, increases mammary carcinogenesis in a rodent model. In vitro studies have suggested that bisphenol A can promote the growth of neuroblastoma cells and potentially promotes invasion and metastasis of neuroblastoma cells. Newborn rats exposed to a low-dose of bisphenol A (10 ug/kg) showed increased prostate cancer susceptibility when adults. At least one study has suggested that bisphenol A suppresses DNA methylation which is involved in epigenetic changes.

Bisphenol A is the isopropyl adduct of 4,4'-dihydroxydiphenyl oxide (DHDPO). A series of DHDPO analogues have been investigated as potential oestrogen receptor/anti-tumour drug carriers in the development of a class of therapeutic drugs called "cytostatic hormones".

Oestrogenic activity is induced with 1 to 100 mg/kg body weight in animal models. Bisphenol A sealants are frequently used in dentistry for treatment of dental pits and fissures. Samples of saliva collected from dental patients during a 1-hour period following application contain the



monomer. A bisphenol-A sealant has been shown to be oestrogenic in vitro; such sealants may represent an additional source of xenoestrogens in humans and may be the cause of additional concerns in children.

Concerns have been raised about the possible developmental effects on the foetus/embryo or neonate resulting from the leaching of bisphenol A from epoxy linings in metal cans which come in contact with food-stuffs.

Many drugs, including naproxen, salicylic acid, carbamazepine and mefenamic acid can, in vitro, significantly inhibit bisphenol A glucuronidation (detoxification).

BPA belongs to the list of compounds having this property as the rodent models have shown that BPA exposure is linked with increased body weight (obesogens). Several mechanisms can help explain the effect of BPA on body weight increase. A possible mechanism leading to triglyceride accumulation is the decreased production of the hormone adiponectin from all human adipose tissue tested when exposed to very low levels (below nanomolar range) of BPA in cell or explant culture settings. The expression of leptin as well as several enzymes and transcription factors is also affected by BPA exposure in vivo as well as in vitro. Together, the altered expression and activity of these important mediators of fat metabolism could explain the increase in weight following BPA exposure in rodent models. These results also suggest that, together with other obesogens, low, environmentally relevant levels of BPA may contribute to the human obesity phenomenon.

Bisphenol F, bisphenol A, fluorine-containing bisphenol A (bisphenol AF), and other diphenylalkanes were found to be oestrogenic in a bioassay with MCF7 human breast cancer cells in culture Bisphenol F (4,4'-dihydroxydiphenylmethane) has been reported to exhibit oestrogen agonistic properties in the uterotrophic assay. Bisphenol F (BPF) is present in the environment and as a contaminant of food. Humans may, therefore, be exposed to BP. BPF has been shown to have genotoxic and endocrine-disruptor properties in a human hepatoma cell line (HepG2), which is a model system for studies of xenobiotic toxicity. BPF was largely metabolised into the corresponding sulfate by the HepG2 cell line. BPF was metabolised into both sulfate and glucuronide by human hepatocytes, but with differences between individuals. The metabolism of BPF in both HepG2 cells and human hepatocytes suggests the existence of a detoxification pathway

Bisphenol F was orally administered at doses 0, 20, 100 and 500 mg/kg per day for at least 28 days, but no clear endocrine-mediated changes were detected, and it was concluded to have no endocrine-mediated effects in young adult rats. On the other hand, the main effect of bisphenol F was concluded to be liver toxicity based on clinical biochemical parameters and liver weight, but without histopathological changes. The no-observed-effect level for bisphenol F is concluded to be under 20 mg/kg per day since decreased body weight accompanied by decreased serum total cholesterol, glucose, and albumin values were observed in the female rats given 20 mg/kg per day or higher doses of bisphenol F.

ARDEX EG800F Part A	<b>TOXICITY</b>	<b>IRRITATION</b>
	Not Available	Not Available
bisphenol A/ diglycidyl ether resin, liquid	<b>TOXICITY</b>	<b>IRRITATION</b>
	dermal (rat) LD50: >1200 mg/kg <sup>[2]</sup>	Eye (Rodent - rabbit): 100mg - Mild
	Oral (Mouse) LD50: >500 mg/kg <sup>[2]</sup>	Eye (Rodent - rabbit): 100mg - Mild
		Eye (Rodent - rabbit): 100mg - Mild
		Eye (Rodent - rabbit): 20mg/24H - Moderate
		Eye (Rodent - rabbit): 5mg/24H - Severe
		Skin (Rodent - guinea pig): 2750mg/55D (intermittent)
bisphenol A diglycidyl ether	<b>TOXICITY</b>	<b>IRRITATION</b>
	dermal (rat) LD50: >2000 mg/kg <sup>[1]</sup>	Eye (Rodent - rabbit): 100mg - Mild
	Oral (Rat) LD50: >2000 mg/kg <sup>[1]</sup>	Eye (Rodent - rabbit): 100mg - Mild
		Eye (Rodent - rabbit): 100mg - Mild
		Eye (Rodent - rabbit): 20mg/24H - Moderate
		Eye (Rodent - rabbit): 2mg/24H - Severe
		Eye (Rodent - rabbit): 5mg/24H - Severe
		Eye: adverse effect observed (irritating) <sup>[1]</sup>
		Skin (Rodent - guinea pig): 2750mg/55D (intermittent)
		Skin (Rodent - rabbit): 2mg/24H - Severe
glycidyl neodecanoate	<b>TOXICITY</b>	<b>IRRITATION</b>
	dermal (rat) LD50: >4 mg/kg <sup>[2]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
	Inhalation (Rat) LC50: >0.25 mg/l4h <sup>[2]</sup>	Skin (Rodent - rabbit): 0.5mL - Moderate
	Oral (Rat) LD50: >10 mg/kg <sup>[2]</sup>	Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
bisphenol F diglycidyl ether (isomers)	<b>TOXICITY</b>	<b>IRRITATION</b>
	Dermal (rabbit) LD50: >6000 mg/kg <sup>[2]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
	Oral (Rat) LD50: >4000 mg/kg <sup>[2]</sup>	Skin (Rodent - rabbit): 500uL/24H - Mild
		Skin: adverse effect observed (irritating) <sup>[1]</sup>
(C12-14)alkylglycidyl ether	<b>TOXICITY</b>	<b>IRRITATION</b>
	Oral (Rat) LD50: >10000 mg/kg <sup>[2]</sup>	Eye: adverse effect observed (irritating) <sup>[1]</sup>
		Skin (Rodent - rabbit): 500uL/24H - Moderate
		Skin: adverse effect observed (irritating) <sup>[1]</sup>
cresyl glycidyl ether	<b>TOXICITY</b>	<b>IRRITATION</b>

dermal (mouse) LD50: 480 mg/kg <sup>[2]</sup>	Skin (Rodent - rabbit): 500uL/24H - Severe
Inhalation (Rat) LC50: 4.8-8.5 mg/l4h <sup>[2]</sup>	
Oral (Rat) LD50: 5140 mg/kg <sup>[2]</sup>	

**Legend:** 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

#### BISPHENOL A/ DIGLYCIDYL ETHER RESIN, LIQUID

Foototoxicity has been observed in animal studies Oral (rabbit, female) NOEL 180 mg/kg (teratogenicity); NOEL (maternal 60 mg/kg

Bisphenol A exhibits hormone-like properties that raise concern about its suitability in consumer products and food containers. Bisphenol A is thought to be an endocrine disruptor which can mimic oestrogen and may lead to negative health effects. More specifically, bisphenol A closely mimics the structure and function of the hormone oestradiol with the ability to bind to and activate the same oestrogen receptor as the natural hormone. The presence of the p-hydroxy group on the benzene rings is thought to be responsible for the oestradiol mimicry. Early developmental stages appear to be the period of greatest sensitivity to its effects and some studies have linked prenatal exposure to later physical and neurological difficulties. Regulatory bodies have determined safety levels for humans, but those safety levels are being questioned or are under review.

A 2009 study on Chinese workers in bisphenol A factories found that workers were four times more likely to report erectile dysfunction, reduced sexual desire and overall dissatisfaction with their sex life than workers with no heightened bisphenol A exposure. Bisphenol A workers were also seven times more likely to have ejaculation difficulties. They were also more likely to report reduced sexual function within one year of beginning employment at the factory, and the higher the exposure, the more likely they were to have sexual difficulties.

Bisphenol A in weak concentrations is sufficient to produce a negative reaction on the human testicle. The researchers found that a concentration equal to 2 ug/ litre of bisphenol A in the culture medium, a concentration equal to the average concentration generally found in the blood, urine and amniotic fluid of the population, was sufficient to produce the effects. The researchers believe that exposure of pregnant women to bisphenol A may be one of the causes of congenital masculinisation defects of the hypospadias and cryptorchidism types the frequency of which has doubled overall since the 70's. They also suggested that "it is also possible that bisphenol A contributes to a reduction in the production of sperm and the increase in the incidence of testicular cancer in adults that have been observed in recent decades"

One review has concluded that obesity may be increased as a function of bisphenol A exposure, which "...merits concern among scientists and public health officials"

One study demonstrated that adverse neurological effects occur in non-human primates regularly exposed to bisphenol A at levels equal to the United States Environmental Protection Agency's (EPA) maximum safe dose of 50 ug/kg/day This research found a connection between bisphenol A and interference with brain cell connections vital to memory, learning, and mood.

A further review concluded that bisphenol-A has been shown to bind to thyroid hormone receptor and perhaps have selective effects on its functions. Carcinogenicity studies have shown increases in leukaemia and testicular interstitial cell tumours in male rats. However, "these studies have not been considered as convincing evidence of a potential cancer risk because of the doubtful statistical significance of the small differences in incidences from controls". Another in vitro study has concluded that bisphenol A is able to induce neoplastic transformation in human breast epithelial cells.[whilst a further study concluded that maternal oral exposure to low concentrations of bisphenol A, during lactation, increases mammary carcinogenesis in a rodent model. In vitro studies have suggested that bisphenol A can promote the growth of neuroblastoma cells and potentially promotes invasion and metastasis of neuroblastoma cells. Newborn rats exposed to a low-dose of bisphenol A (10 ug/kg) showed increased prostate cancer susceptibility when adults. At least one study has suggested that bisphenol A suppresses DNA methylation which is involved in epigenetic changes.

Bisphenol A is the isopropyl adduct of 4,4'-dihydroxydiphenyl oxide (DHDPO). A series of DHDPO analogues have been investigated as potential oestrogen receptor/anti-tumour drug carriers in the development of a class of therapeutic drugs called "cytostatic hormones". Oestrogenic activity is induced with 1 to 100 mg/kg body weight in animal models. Bisphenol A sealants are frequently used in dentistry for treatment of dental pits and fissures. Samples of saliva collected from dental patients during a 1-hour period following application contain the monomer. A bisphenol-A sealant has been shown to be oestrogenic in vitro; such sealants may represent an additional source of xenoestrogens in humans and may be the cause of additional concerns in children.

Concerns have been raised about the possible developmental effects on the foetus/embryo or neonate resulting from the leaching of bisphenol A from epoxy linings in metal cans which come in contact with food-stuffs.

Many drugs, including naproxen, salicylic acid, carbamazepine and mefenamic acid can, in vitro, significantly inhibit bisphenol A glucuronidation (detoxification).

BPA belongs to the list of compounds having this property as the rodent models have shown that BPA exposure is linked with increased body weight (obesogens). Several mechanisms can help explain the effect of BPA on body weight increase. A possible mechanism leading to triglyceride accumulation is the decreased production of the hormone adiponectin from all human adipose tissue tested when exposed to very low levels (below nanomolar range) of BPA in cell or explant culture settings. The expression of leptin as well as several enzymes and transcription factors is also affected by BPA exposure in vivo as well as in vitro. Together, the altered expression and activity of these important mediators of fat metabolism could explain the increase in weight following BPA exposure in rodent models. These results also suggest that, together with other obesogens, low, environmentally relevant levels of BPA may contribute to the human obesity phenomenon.

All glycidyl ethers show genotoxic potential due their alkylating properties. Those glycidyl ethers that have been investigated in long term studies exhibit more or less marked carcinogenic potential. Alkylating agents may damage the stem cell which acts as the precursor to components of the blood. Loss of the stem cell may result in pancytopenia (a reduction in the number of red and white blood cells and platelets) with a latency period corresponding to the lifetime of the individual blood cells. Granulocytopenia (a reduction in granular leukocytes) develops within days and thrombocytopenia (a disorder involving platelets), within 1-2 weeks, whilst loss of erythrocytes (red blood cells) need months to become clinically manifest. Aplastic anaemia develops due to complete destruction of the stem cells.

Reported adverse effects in laboratory animals include sensitization, and skin and eye irritation, as well as mutagenic and tumorigenic activity..

Testicular abnormalities (including testicular atrophy with decreased spermatogenic activity) following exposure to glycidyl ethers have been reported. Haemopoietic abnormalities following exposure to glycidyl ethers, including alteration of the leukocyte count, atrophy of lymphoid tissue, and bone marrow cytotoxicity have also been reported. These abnormalities were usually observed along with pneumonia and/or toxemia, and therefore may be secondary effects. However, especially in light of the generalized reduction in leukocytes and the atrophy of lymphoid tissues, the observed haemopoietic abnormalities may have been predisposing factors to pneumonia. While none of the individual research reports are conclusive with respect to the ability of glycidyl ethers to produce permanent changes to the testes or haemopoietic system in laboratory animals, the pattern of displayed effects is reason for concern

Glycidyl ethers have been shown to cause allergic contact dermatitis in humans. Glycidyl ethers generally cause skin sensitization in experimental animals. Necrosis of the mucous membranes of the nasal cavities was induced in mice exposed to allyl glycidyl ether.

A study of workers with mixed exposures was inconclusive with regard to the effects of specific glycidyl ethers. Phenyl glycidyl ether, but not n-butyl glycidyl ether, induced morphological transformation in mammalian cells in vitro. n-Butyl glycidyl ether induced micronuclei in mice in vivo following intraperitoneal but not oral administration. Phenyl glycidyl ether did not induce micronuclei or chromosomal aberrations in vivo or chromosomal aberrations in animal cells in vitro. Alkyl C12 or C14 glycidyl ether did not induce DNA damage in cultured human cells or mutation in cultured animal cells. Allyl glycidyl ether induced mutation in Drosophila. The glycidyl ethers were generally mutagenic to bacteria.

55badger

#### GLYCIDYL NEODECANOATE

Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies.

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating

	<p>compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.</p> <p>Fatty acid glycidyl esters (GEs) are potential carcinogens, due to the fact that they readily hydrolyze into the free form glycidol (2,3-epoxypropanol) in the gastrointestinal tract, which has been found to induce tumours in various rat tissues. Therefore, significant effort has been devoted to inhibit and eliminate the formation of GEs</p> <p>Exposure to glycidol may also cause central nervous system depression, followed by central nervous system stimulation. Although harmful effects on humans and animals have not been demonstrated, the corresponding hydrolysates, 3-MCPD and glycidol, have been identified as rodent genotoxic carcinogens, ultimately resulting in the formation of kidney tumours (3-MCPD) and tumours at other tissue sites (glycidol). Therefore, 3-MCPD and glycidol have been categorised as "possible human carcinogens (group 2B) and "probably carcinogenic to humans (group 2A), respectively, by the International Agency for Research on Cancer (IARC).</p> <p>Diacylglyceride (DAG) based oils produced by one company were banned from the global market due to "high levels" of GEs.</p> <p>No significant acute toxicological data identified in literature search.</p> <p>For glycidyl neodecanoate</p> <p>The material has a low order of acute toxicity by the oral, dermal, and inhalation routes of exposure. It is mildly irritating to the eyes and non-irritating to the skin. Dermal sensitisation has been observed in guinea pigs and has been reported in humans following occupational exposure. In vitro genotoxicity testing indicated weak mutagenic activity in point mutation assays with metabolic activation using Salmonella, but not in E. coli or yeast. Mutagenic activity was not observed in an in vitro mammalian cell assay. A weak ability to produce chromosomal damage was observed in cultured rat liver cells, but no DNA damage was produced in an in vivo rat liver assay. A low order of toxicity was observed in subchronic dietary testing with a No Observed Adverse Effect Level (NOAEL) of 1000 ppm in the diet. At high concentrations of 5000 and 10000 ppm in the diet, kidney effects were observed that were more prominent in males than in females. No effects were noted in reproductive organs of either sex. Further testing to evaluate potential developmental or reproductive effects has not been identified.</p> <p>Acute Toxicity</p> <p>The material has a low order of acute toxicity by the oral, dermal, and inhalation routes of exposure. In rats, the oral LD50 was greater than 10 ml/kg (approximately 10 g/kg) and the dermal LD50 was greater than 4 ml/kg (approximately 4 g/kg). The rat 4-hour inhalation LC50 was greater than 0.24 mg/L (approximately 240 mg/m<sup>3</sup>), a concentration exceeding the saturated vapor pressure. Due to the low vapor pressure resulting in a low level of maximal attainable vapor concentration, inhalation exposure is expected to pose a negligible hazard.</p> <p>Repeated Dose Toxicity</p> <p>A low order of toxicity was observed in rats following five-week dietary testing. Treatment-related effects were limited to the upper two dietary dose levels of 5,000 and 10,000 ppm (approximately 478 and 888 mg/kg/day body weight, respectively). Dose-related effects at these two dietary levels included: decreased food intake and body weights, minor changes in hematology and clinical chemistry, increased liver and kidney weights and nephrotoxicity to the proximal tubules of the kidneys that was more pronounced in males than in females. The Lowest Observed Adverse Effect Level (LOAEL) was 5,000 ppm in the diet (approximately 478 mg/kg/day body weight) and the No Observed Adverse Effect Level (NOAEL) was 1,000 ppm in the diet (approximately 96 mg/kg/day body weight).</p> <p>* HPV Chemical Challenge Program 2003</p>
<p><b>BISPHENOL F DIGLYCIDYL ETHER (ISOMERS)</b></p>	<p>Ames test with and without microsomal activation: Positive ** [Ciba-Geigy] * [Dexter Electronic Materials]</p> <p>The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.</p>
<p><b>CRESYL GLYCIDYL ETHER</b></p>	<p>Mutagenic to bacteria</p>
<p><b>BISPHENOL A/ DIGLYCIDYL ETHER RESIN, LIQUID &amp; BISPHENOL A DIGLYCIDYL ETHER &amp; GLYCIDYL NEODECANOATE &amp; BISPHENOL F DIGLYCIDYL ETHER (ISOMERS) &amp; (C12-14)ALKYLGLYCIDYL ETHER &amp; CRESYL GLYCIDYL ETHER</b></p>	<p>The following information refers to contact allergens as a group and may not be specific to this product.</p> <p>Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.</p>
<p><b>BISPHENOL A/ DIGLYCIDYL ETHER RESIN, LIQUID &amp; BISPHENOL F DIGLYCIDYL ETHER (ISOMERS)</b></p>	<p>The chemical structure of hydroxylated diphenylalkanes or bisphenols consists of two phenolic rings joined together through a bridging carbon. This class of endocrine disruptors that mimic oestrogens is widely used in industry, particularly in plastics.</p> <p>Bisphenol A (BPA) and some related compounds exhibit oestrogenic activity in human breast cancer cell line MCF-7, but there were remarkable differences in activity. Several derivatives of BPA exhibited significant thyroid hormonal activity towards rat pituitary cell line GH3, which releases growth hormone in a thyroid hormone-dependent manner. However, BPA and several other derivatives did not show such activity. Results suggest that the 4-hydroxyl group of the A-phenyl ring and the B-phenyl ring of BPA derivatives are required for these hormonal activities, and substituents at the 3,5-positions of the phenyl rings and the bridging alkyl moiety markedly influence the activities.</p> <p>Bisphenols promoted cell proliferation and increased the synthesis and secretion of cell type-specific proteins. When ranked by proliferative potency, the longer the alkyl substituent at the bridging carbon, the lower the concentration needed for maximal cell yield; the most active compound contained two propyl chains at the bridging carbon. Bisphenols with two hydroxyl groups in the para position and an angular configuration are suitable for appropriate hydrogen bonding to the acceptor site of the oestrogen receptor.</p> <p>In vitro cell models were used to evaluate the ability of 22 bisphenols (BPs) to induce or inhibit estrogenic and androgenic activity. BPA, Bisphenol AF (BPAF), bisphenol Z (BPZ), bisphenol C (BPC), tetramethyl bisphenol A (TMBPA), bisphenol S (BPS), bisphenol E (BPE), 4,4-bisphenol F (4,4-BPF), bisphenol AP (BPAP), bisphenol B (BPB), tetrachlorobisphenol A (TCBPA), and benzylparaben (PHBB) induced estrogen receptor (ER)alpha and/or ERbeta-mediated activity. With the exception of BPS, TCBPA, and PHBB, these same BPs were also androgen receptor (AR) antagonists. Only 3 BPs were found to be ER antagonists. Bisphenol P (BPP) selectively inhibited ERbeta-mediated activity and 4-(4-phenylmethoxyphenyl)sulfonylphenol (BPS-MPE) and 2,4-bisphenol S (2,4-BPS) selectively inhibited ERalpha-mediated activity. None of the BPs induced AR-mediated activity.</p>
<p><b>BISPHENOL A/ DIGLYCIDYL ETHER RESIN, LIQUID &amp; BISPHENOL A DIGLYCIDYL ETHER</b></p>	<p>The substance is classified by IARC as Group 3: <b>NOT</b> classifiable as to its carcinogenicity to humans.</p> <p>Evidence of carcinogenicity may be inadequate or limited in animal testing.</p> <p>In mice, dermal application of bisphenol A diglycidyl ether (BADGE) (1, 10, or 100 mg/kg) for 13 weeks produced mild to moderate chronic active dermatitis. At the high dose, spongiosis and epidermal micro abscess formation were observed. In rats, dermal application of BADGE (10, 100, or 1000 mg/kg) for 13 weeks resulted in a decrease in body weight at the high dose. The no-observable effect level (NOEL) for dermal exposure was 100 mg/kg for both sexes. In a separate study, application of BADGE (same doses) five times per week for ~13 weeks not only caused a decrease in body weight but also produced chronic dermatitis at all dose levels in males and at &gt;100 mg/kg in females (as well as in a satellite group of females given 1000 mg/kg).</p> <p><b>Reproductive and Developmental Toxicity:</b> BADGE (50, 540, or 750 mg/kg) administered to rats via gavage for 14 weeks (P1) or 12 weeks (P2) produced decreased body weight in all males at the mid dose and in both males and females at the high dose, but had no reproductive effects. The NOEL for reproductive effects was 750 mg/kg.</p> <p><b>Carcinogenicity:</b> IARC concluded that "there is limited evidence for the carcinogenicity of bisphenol A diglycidyl ether in experimental animals." Its overall evaluation was "Bisphenol A diglycidyl ether is not classifiable as to its carcinogenicity to humans (Group 3).</p> <p>In a lifetime tumourigenicity study in which 90-day-old C3H mice received three dermal applications per week of BADGE (undiluted dose) for 23 months, only one out of 32 animals developed a papilloma after 16 months. A retest, in which skin paintings were done for 27 months, however, produced no tumours (Weil et al., 1963). In another lifetime skin-painting study, BADGE (dose n.p.) was also reported to be noncarcinogenic to the skin of C3H mice; it was, however, weakly carcinogenic to the skin of C57BL/6 mice (Holland et al., 1979; cited by Canter et al., 1986). In a two-year bioassay, female Fisher 344 rats dermally exposed to BADGE (1, 100, or 1000 mg/kg) showed no evidence of dermal carcinogenicity but did have low incidences of tumours in the oral cavity (U.S. EPA, 1997).</p>

**Genotoxicity:** In *S. typhimurium* strains TA100 and TA1535, BADGE (10-10,000 ug/plate) was mutagenic with and without S9; negative results were obtained in TA98 and TA1537 (Canter et al., 1986; Pullin, 1977). In a spot test, BADGE (0.05 or 10.00 mg) failed to show mutagenicity in strains TA98 and TA100 (Wade et al., 1979). Negative results were also obtained in the body fluid test using urine of female BDF and ICR mice (1000 mg/kg BADGE), the mouse host-mediated assay (1000 mg/kg), micronucleus test (1000 mg/kg), and dominant lethal assay (~3000 mg/kg).

**Immunotoxicity:** Intracutaneous injection of diluted BADGE (0.1 mL) three times per week on alternate days (total of 8 injections) followed by a three-week incubation period and a challenge dose produced sensitisation in 19 of 20 guinea pigs

**Consumer exposure** to BADGE is almost exclusively from migration of BADGE from can coatings into food. Using a worst-case scenario that assumes BADGE migrates at the same level into all types of food, the estimated per capita daily intake for a 60-kg individual is approximately 0.16 ug/kg body weight/day. A review of one- and two-generation reproduction studies and developmental investigations found no evidence of reproductive or endocrine toxicity, the upper ranges of dosing being determined by maternal toxicity. The lack of endocrine toxicity in the reproductive and developmental toxicological tests is supported by negative results from both in vivo and in vitro assays designed specifically to detect oestrogenic and androgenic properties of BADGE. An examination of data from sub-chronic and chronic toxicological studies support a NOAEL of 50 mg/ kg/body weight day from the 90-day study, and a NOAEL of 15 mg/kg body weight/day (male rats) from the 2-year carcinogenicity study. Both NOAELs are considered appropriate for risk assessment. Comparing the estimated daily human intake of 0.16 ug/kg body weight/day with the NOAELs of 50 and 15 mg/kg body weight/day shows human exposure to BADGE from can coatings is between 250,000 and 100,000-fold lower than the NOAELs from the most sensitive toxicology tests. These large margins of safety together with lack of reproductive, developmental, endocrine and carcinogenic effects supports the continued use of BADGE for use in articles intended to come into contact with foodstuffs.

**BISPHENOL A DIGLYCIDYL ETHER & GLYCIDYL NEODECANOATE & BISPHENOL F DIGLYCIDYL ETHER (ISOMERS) & (C12-14)ALKYLGLYCIDYL ETHER**

Oxiranes (including glycidyl ethers and alkyl oxides, and epoxides) exhibit many common characteristics with respect to animal toxicology. One such oxirane is ethyloxirane; data presented here may be taken as representative.

**BISPHENOL A DIGLYCIDYL ETHER & GLYCIDYL NEODECANOATE & (C12-14)ALKYLGLYCIDYL ETHER**

for 1,2-butylene oxide (ethyloxirane):

Ethyloxirane increased the incidence of tumours of the respiratory system in male and female rats exposed via inhalation. Significant increases in nasal papillary adenomas and combined alveolar/bronchiolar adenomas and carcinomas were observed in male rats exposed to 1200 mg/m<sup>3</sup> ethyloxirane via inhalation for 103 weeks. There was also a significant positive trend in the incidence of combined alveolar/bronchiolar adenomas and carcinomas. Nasal papillary adenomas were also observed in 2/50 high-dose female rats with none occurring in control or low-dose animals. In mice exposed chronically via inhalation, one male mouse developed a squamous cell papilloma in the nasal cavity (300 mg/m<sup>3</sup>) but other tumours were not observed. Tumours were not observed in mice exposed chronically via dermal exposure. When trichloroethylene containing 0.8% ethyloxirane was administered orally to mice for up to 35 weeks, followed by 0.4% from weeks 40 to 69, squamous-cell carcinomas of the forestomach occurred in 3/49 males (p=0.029, age-adjusted) and 1/48 females at week 106. Trichloroethylene administered alone did not induce these tumours and they were not observed in control animals. Two structurally related substances, oxirane (ethylene oxide) and methyloxirane (propylene oxide), which are also direct-acting alkylating agents, have been classified as carcinogenic

Acute Toxicity	✗	Carcinogenicity	✓
Skin Irritation/Corrosion	✓	Reproductivity	✗
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✗
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	✓
Mutagenicity	✓	Aspiration Hazard	✗

**Legend:** ✗ – Data either not available or does not fill the criteria for classification  
 ✓ – Data available to make classification

## SECTION 12 Ecological information

### Toxicity

ARDEX EG800F Part A	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
bisphenol A/ diglycidyl ether resin, liquid	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	~2mg/l	2
	EC50(ECx)	48h	Crustacea	~2mg/l	2
bisphenol A diglycidyl ether	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	72h	Algae or other aquatic plants	9.4mg/l	2
	EC50	48h	Crustacea	1.1mg/l	2
	LC50	96h	Fish	1.2mg/l	2
	NOEC(ECx)	504h	Crustacea	0.3mg/l	2
glycidyl neodecanoate	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	96h	Algae or other aquatic plants	1mg/l	1
	EC50	96h	Algae or other aquatic plants	3.5mg/l	1
	EC50	72h	Algae or other aquatic plants	~1.2mg/l	2
	EC50	48h	Crustacea	4.8mg/l	1
	LC50	96h	Fish	~5mg/l	2
bisphenol F diglycidyl ether (isomers)	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	1.6mg/l	2
	EC50	72h	Algae or other aquatic plants	>1.8mg/l	2
	LC50	96h	Fish	0.55mg/l	2

Continued...

	NOEC(ECx)	504h	Crustacea	0.3mg/l	2
<b>(C12-14)alkylglycidyl ether</b>	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	6.07mg/l	2
	LC50	96h	Fish	>5000mg/l	2
	EC50(ECx)	48h	Crustacea	6.07mg/l	2
<b>cresyl glycidyl ether</b>	Endpoint	Test Duration (hr)	Species	Value	Source
	LC50	96h	Fish	1-10mg/l	Not Available
	EC50	72h	Algae or other aquatic plants	~5.1mg/l	2
	EC50	48h	Crustacea	~3.3mg/l	2
	EC50(ECx)	24h	Crustacea	1-10mg/l	Not Available

**Legend:** Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

**DO NOT discharge into sewer or waterways.**

Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

**Persistence and degradability**

Ingredient	Persistence: Water/Soil	Persistence: Air
bisphenol A/ diglycidyl ether resin, liquid	HIGH	HIGH
bisphenol A diglycidyl ether	HIGH	HIGH
glycidyl neodecanoate	HIGH	HIGH
cresyl glycidyl ether	LOW (Half-life = 49 days)	LOW (Half-life = 0.67 days)

**Bioaccumulative potential**

Ingredient	Bioaccumulation
bisphenol A/ diglycidyl ether resin, liquid	LOW (LogKOW = 2.6835)
bisphenol A diglycidyl ether	MEDIUM (LogKOW = 3.8446)
glycidyl neodecanoate	LOW (LogKOW = 3.7305)
cresyl glycidyl ether	LOW (LogKOW = 2.1609)

**Mobility in soil**

Ingredient	Mobility
bisphenol A/ diglycidyl ether resin, liquid	LOW (Log KOC = 51.43)
bisphenol A diglycidyl ether	LOW (Log KOC = 1767)
glycidyl neodecanoate	LOW (Log KOC = 105.5)
cresyl glycidyl ether	LOW (Log KOC = 66.54)

**SECTION 13 Disposal considerations**

**Waste treatment methods**

<b>Product / Packaging disposal</b>	<ul style="list-style-type: none"> <li>Containers may still present a chemical hazard/ danger when empty.</li> <li>Return to supplier for reuse/ recycling if possible.</li> </ul> <p>Otherwise:</p> <ul style="list-style-type: none"> <li>If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.</li> <li>Where possible retain label warnings and SDS and observe all notices pertaining to the product.</li> </ul> <p><b>Waste Management</b></p> <p>Production waste from epoxy resins and resin systems should be treated as hazardous waste in accordance with National regulations. Fire retarded resins containing halogenated compounds should also be treated as special waste. Accidental spillage of resins, curing agents and their formulations should be contained and absorbed by special mineral absorbents to prevent them from entering the environment. Contaminated or surplus product should not be washed down the sink, but preferably be fully reacted to form cross-linked solids which is non-hazardous and can be more easily disposed.</p> <p>Finished articles made from fully cured epoxy resins are hard, infusible solids presenting no hazard to the environment. However, finished articles from flame-retarded material containing halogenated resins should be considered hazardous waste, and disposed as required by National laws. Articles made from epoxy resins, like other thermosets, can be recycled by grinding and used as fillers in other products. Another way of disposal and recovery is combustion with energy recovery.</p> <ul style="list-style-type: none"> <li><b>DO NOT allow wash water from cleaning or process equipment to enter drains.</b></li> <li>It may be necessary to collect all wash water for treatment before disposal.</li> <li>In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.</li> <li>Where in doubt contact the responsible authority.</li> </ul> <p>Removal of bisphenol A (BPA) from aqueous solutions was accomplished by adsorption of enzymatically generated quinone derivatives on chitosan beads. The use of chitosan in the form of beads was found to be more effective because heterogeneous removal of BPA with chitosan beads was much faster than homogeneous removal of BPA with chitosan solutions, and the removal efficiency was enhanced by increasing the amount of chitosan beads dispersed in the BPA solutions and BPA was completely removed by quinone adsorption in the presence of chitosan beads more than 0.10 cm<sup>3</sup>/cm<sup>3</sup>. In addition, a variety of bisphenol derivatives were completely or effectively removed by the procedure constructed in this study, although the enzyme dose or the amount of chitosan beads was further increased as necessary for some of the bisphenol derivatives used.</p>
-------------------------------------	---

Continued...





ARDEX EG800F Part A

- M. Suzuki, and E Musashi J Appl Polym Sci, 118(2):721 - 732; October 2010
- ▶ Recycle wherever possible or consult manufacturer for recycling options.
  - ▶ Consult State Land Waste Authority for disposal.
  - ▶ Bury or incinerate residue at an approved site.
  - ▶ Recycle containers if possible, or dispose of in an authorised landfill.

**SECTION 14 Transport information**

**Labels Required**

	
Marine Pollutant	
HAZCHEM	•3Z

**Land transport (ADG)**

14.1. UN number or ID number	3082	
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains bisphenol A diglycidyl ether and bisphenol A/ diglycidyl ether resin, liquid)	
14.3. Transport hazard class(es)	Class	9
	Subsidiary Hazard	Not Applicable
14.4. Packing group	III	
14.5. Environmental hazard	Environmentally hazardous	
14.6. Special precautions for user	Special provisions	274 331 335 375 AU01
	Limited quantity	5 L

Environmentally Hazardous Substances meeting the descriptions of UN 3077 or UN 3082 are not subject to this Code when transported by road or rail in;

(a) packagings;

(b) IBCs; or

(c) any other receptacle not exceeding 500 kg(L).

- Australian Special Provisions (SP AU01) - ADG Code 7th Ed.

**Air transport (ICAO-IATA / DGR)**

14.1. UN number	3082	
14.2. UN proper shipping name	Environmentally hazardous substance, liquid, n.o.s. (contains bisphenol A diglycidyl ether and bisphenol A/ diglycidyl ether resin, liquid)	
14.3. Transport hazard class(es)	ICAO/IATA Class	9
	ICAO / IATA Subsidiary Hazard	Not Applicable
	ERG Code	9L
14.4. Packing group	III	
14.5. Environmental hazard	Environmentally hazardous	
14.6. Special precautions for user	Special provisions	A97 A158 A197 A215
	Cargo Only Packing Instructions	964
	Cargo Only Maximum Qty / Pack	450 L
	Passenger and Cargo Packing Instructions	964
	Passenger and Cargo Maximum Qty / Pack	450 L
	Passenger and Cargo Limited Quantity Packing Instructions	Y964
	Passenger and Cargo Limited Maximum Qty / Pack	30 kg G

**Sea transport (IMDG-Code / GGVSee)**

14.1. UN number	3082	
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains bisphenol A diglycidyl ether and bisphenol A/ diglycidyl ether resin, liquid)	
14.3. Transport hazard class(es)	IMDG Class	9
	IMDG Subsidiary Hazard	Not Applicable
14.4. Packing group	III	
14.5. Environmental hazard	Marine Pollutant	
14.6. Special precautions for user	EMS Number	F-A, S-F



Special provisions	274 335 969
Limited Quantities	5 L

**14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code**

Not Applicable

**14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code**

Product name	Group
bisphenol A/ diglycidyl ether resin, liquid	Not Available
bisphenol A diglycidyl ether	Not Available
glycidyl neodecanoate	Not Available
bisphenol F diglycidyl ether (isomers)	Not Available
(C12-14)alkylglycidyl ether	Not Available
cresyl glycidyl ether	Not Available

**14.7.3. Transport in bulk in accordance with the IGC Code**

Product name	Ship Type
bisphenol A/ diglycidyl ether resin, liquid	Not Available
bisphenol A diglycidyl ether	Not Available
glycidyl neodecanoate	Not Available
bisphenol F diglycidyl ether (isomers)	Not Available
(C12-14)alkylglycidyl ether	Not Available
cresyl glycidyl ether	Not Available

**SECTION 15 Regulatory information****Safety, health and environmental regulations / legislation specific for the substance or mixture****bisphenol A/ diglycidyl ether resin, liquid is found on the following regulatory lists**

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals  
 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5  
 Australian Inventory of Industrial Chemicals (AIIC)  
 Chemical Footprint Project - Chemicals of High Concern List  
 International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

**bisphenol A diglycidyl ether is found on the following regulatory lists**

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals  
 Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5  
 Australian Inventory of Industrial Chemicals (AIIC)  
 Chemical Footprint Project - Chemicals of High Concern List  
 International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic  
 International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

**glycidyl neodecanoate is found on the following regulatory lists**

Australian Inventory of Industrial Chemicals (AIIC)

**bisphenol F diglycidyl ether (isomers) is found on the following regulatory lists**

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals  
 Australian Inventory of Industrial Chemicals (AIIC)  
 Chemical Footprint Project - Chemicals of High Concern List

**(C12-14)alkylglycidyl ether is found on the following regulatory lists**

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals  
 Australian Inventory of Industrial Chemicals (AIIC)  
 Chemical Footprint Project - Chemicals of High Concern List

**cresyl glycidyl ether is found on the following regulatory lists**

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals  
 Australian Inventory of Industrial Chemicals (AIIC)  
 Chemical Footprint Project - Chemicals of High Concern List

**Additional Regulatory Information**

Not Applicable

**National Inventory Status**

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes

National Inventory	Status
Canada - NDSL	No (bisphenol A/ diglycidyl ether resin, liquid; bisphenol A diglycidyl ether; glycidyl neodecanoate; (C12-14)alkylglycidyl ether; cresyl glycidyl ether)
China - IECSC	Yes
Europe - EINEC / ELINCS / NLP	Yes
Japan - ENCS	Yes
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	Yes
USA - TSCA	All chemical substances in this product have been designated as TSCA Inventory 'Active'
Taiwan - TCSI	Yes
Mexico - INSQ	No (bisphenol A diglycidyl ether; (C12-14)alkylglycidyl ether; cresyl glycidyl ether)
Vietnam - NCI	Yes
Russia - FBEPH	Yes
<b>Legend:</b>	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

## SECTION 16 Other information

<b>Revision Date</b>	24/10/2024
<b>Initial Date</b>	24/10/2024

### Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

### Definitions and abbreviations

- ▶ PC - TWA: Permissible Concentration-Time Weighted Average
- ▶ PC - STEL: Permissible Concentration-Short Term Exposure Limit
- ▶ IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- ▶ TEEL: Temporary Emergency Exposure Limit,
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ▶ ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- ▶ NOAEL: No Observed Adverse Effect Level
- ▶ LOAEL: Lowest Observed Adverse Effect Level
- ▶ TLV: Threshold Limit Value
- ▶ LOD: Limit Of Detection
- ▶ OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ▶ DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
  
- ▶ AIIC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ▶ IECSC: Inventory of Existing Chemical Substance in China
- ▶ EINECS: European Inventory of Existing Commercial chemical Substances
- ▶ ELINCS: European List of Notified Chemical Substances
- ▶ NLP: No-Longer Polymers
- ▶ ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- ▶ TSCA: Toxic Substances Control Act
- ▶ TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- ▶ NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.